Bristol-myers Squibb Compnay

Bristol Meyers Squibb Company

Derek John Denhart

Jonathan L Ditta

Ronald J Mattson

John E Macor

George O Tora

Andrew P Degnan

Dalton King

Lawrence R Marcin

Jun Yuan

Graham Johnson

Li-Qiang Sun

Joanne J Bronson

Stephen R Bertenshaw

Joseph P Yevich

Gene Michael Dubowchik

Jie Chen

Kevin W Gillman

Ying Han

Ramkumar Rajamani

Katherine S Takaki

John D Catt

Vivekananda M Vrudhula

Zhaoxing Meng

Mendi A Higgins

James R Epperson

Jeffrey A Deskus

David Paul Provencal

Arlene S Eison

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both. 

NK-1 and serotonin transporter inhibitors

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders. 

Substituted heterocyclic ethers and their use in CNS disorders

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.

Compounds for the treatment of premature ejaculation

Cyclopropylindole derivatives as selective serotonin reuptake inhibitors

Novel benzoxazole derivatives which have a binding affinity for the human melatonin receptor and, therefore, are useful as melatonergic agents.

Benzoxazole derivatives as novel melatonergic agents

Antipsychotic heterocycle compounds

The present invention relates to the design, synthesis, and the peptidyl-prolyl isomerase (PPIase or rotamase) inhibitory activity of novel pyrrolidinemethyl diamide and carbamate compounds that are neurotrophic agents (i.e. compounds capable of stimulating growth or proliferation of nervous tissue) and that bind to immunophilins such as FKBP12 and inhibit their rotamase activity. This invention also relates to pharmaceutical compositions comprising these compounds.

Neurotrophic diamide and carbamate agents

Growing community of inventors

Durham, CT, United States of America

Derek John Denhart